Zhiming Shao
Fudan University · Cancer Hospital / Institute, Fudan University
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Zhiming Shao as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 11:13 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT07826052 · Chemotherapy Exemption in Elderly Women With Node-Positive ER+/HER2- Breast CancerFudan University · not yet recruiting · Breast Cancer, Adjuvant Therapy · principal investigator
- Ph2/Ph3NCT07294534 · A Phase II/III Clinical Study to Evaluate the Efficacy and Safety of HLX87in Combination With HLX22 or Pertuzumab in the Neoadjuvant Therapy of HER2-Positive Bresat CancerShanghai Henlius Biotech · not yet recruiting · HER2 + Breast Cancer · principal investigator
- Ph3NCT07005557 · Chemo-free in Older (≥65) Node-Positive ER+/HER2- Breast CancerFudan University · not yet recruiting · Breast Cancer, Adjuvant Therapy · principal investigator
- N/ANCT03507088 · Study to Determine the Utility of FES-PET in the Prediction of Response to Fulvestrant in Women With Estrogen Positive Metastatic Breast CancerZhimin Shao · completed · Metastatic Breast Cancer · principal investigator
- Ph2/Ph3NCT00525642 · Study of Suitable Schedule of Docetaxel,Anthracycline and Cyclophosphamide in Adjuvant Therapy of Beast CancerFudan University · unknown · Breast Neoplasms, Adjuvant, Chemotherapy · study director
Grants
NIH projects from RePORTER, fetched 2026-11-12 11:13 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name in breast cancer, ranked by citations from NIH iCite, fetched 2026-11-12 11:13 UTC. The ranking covers the 200 most relevant of 109 PubMed records, and a shared surname and initials can bring in a namesake. All 109 on PubMed
- Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer.N Engl J Med · 20192,077 citationsRCR 85.1
- Adjuvant Olaparib for Patients with BRCA1- or BRCA2-Mutated Breast Cancer.N Engl J Med · 20211,410 citationsRCR 78.5
- Abemaciclib Combined With Endocrine Therapy for the Adjuvant Treatment of HR+, HER2-, Node-Positive, High-Risk, Early Breast Cancer (monarchE).J Clin Oncol · 2020882 citationsRCR 37.6
- 426 citationsRCR 12.8
- 399 citationsRCR 26.2
- 306 citationsRCR 16.2
- 242 citationsRCR 6.7
- 241 citationsRCR 11.6
- 232 citationsRCR 6.7
- Effect of Adjuvant Paclitaxel and Carboplatin on Survival in Women With Triple-Negative Breast Cancer: A Phase 3 Randomized Clinical Trial.JAMA Oncol · 2020182 citationsRCR 7.0